Artgen Biotech PJSC engages in the discovery, research, development, and marketing of proprietary products and services in the field of regenerative medicine, medical genetics, bio-insurance, gene therapy, and biopharmaceutics. Its research and development involves gemacell and cryocell; service for personal regeneration of bone and of gum; nucleostim; preventive treatment program for primary immunodeficiency diseases; human artificial chromosome; development of drugs using histone proteins; and development of drugs using a novel technology employing polysialic acid. The company was founded by Isaev Alexandrovich Artur on November 3, 2003 and is headquartered in Moscow, Russia.